Abstract: Objective To provide evidence for clinical treatment of urinary tract infections by analyzing the distribution and drug resistance of Escherichia coli from patients with urinary tract infection.Methods Escherichia coli was collected from the samples of urinary tract infections in Jan. 2014 to Dec. 2014 and the strains were identified using BD Phoenix-100 automatic bacterial analyzer. The drug sensitivity test was carried out by MIC method and K-B method.Results The distribution of Escherichia coli was most common in Department Urology, three years accounted for an average of 22.5%, followed by 12.9% of Nephrology, ICU accounted for 11.3%,Geriatrics accounted for 9.6%, Neurology 8.8%, Neurological Intensive Ward 7.9%. The bacteria for clinical experience of first-line drugs ampicillin, cefazolin, sulfamethoxazole, ampicillin/sulbactam resistance rates were relatively high, the three year average resistance rate 93.0%,77.2%,74.1%,81.5%. Levofloxacin of quinolones showed three years the average resistance rate more than 75%, and in three years increased year by year, 2014 compared with 2012 and 2013,the difference was statistically significant(P<0.05).To cefoperazone / sulbactam (15.9%), piperacillin/tazobactam (21.6%), imipenem(3.3%), meropenem (3.3%), the bacteria were more sensitive; low resistance rate on amikacin was 13.2%, but the relatively high rate of gentamicin resistant belonged to aminoglycosides (65.0%).Conclusion The infection distribution and sensitivity of Escherichia coli are constantly changing, so clinicians should choose antibiotics accordingly.

Key words: urinary tract infection, Escherichia coli, antimicrobial resistance